CO-BONA
18.3.2024 09:06:33 CET | Business Wire | Press release
Today, Bona® announced that four of its products are now certified by the U.S. Environmental Protection Agency (EPA) Safer Choice program and have earned the Safer Choice label. The new certification applies to the Bona Pet System™ including Bona Pet System™ Hard-Surface Floor Deep Cleaner and Bona Pet System™ Wood Floor Deep Cleaner as well as Bona’s OxyPower floor cleaners -- Bona OxyPower Hard-Surface Floor Deep Cleaner and Bona OxyPower Wood Floor Deep Cleaner. Safer Choice is a voluntary EPA program that certifies cleaning and other products made with ingredients that are safer for people, pets, and the planet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240318768884/en/
Bona Pet System™ and Bona OxyPower Products Receive Environmental Protection Agency Safer Choice Certification (Graphic: Business Wire)
“As we continue our journey to innovate cleaning solutions that bring out the beauty in floors, our primary focus is to leverage the latest technologies and research when it comes to ingredients,” said Marie Shore, Director Product Management EMEA & APAC, Bona.“Recognition like this one from the EPA Safer Choice program is a key milestone in validating our work for a more sustainable future.”
The Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. Every ingredient in products that carry the Safer Choice label is reviewed by EPA scientists to make sure certified products only contain the safest possible ingredients for people and the planet. Safer Choice-certified products are made with ingredients that won't cause serious health problems, like cancer, and aren't harmful to fish or waterways. Safer Choice also restricts volatile organic compounds to minimize indoor air pollution and associated respiratory concerns. Products with the label also use more sustainable packaging that doesn't contain toxic chemicals, like heavy metals.
Powered by hydrogen peroxide, Bona OxyPower Wood Floor Deep Cleaner and Bona OxyPower Hard-Surface Floor Deep Cleaner are specifically designed to remove heavy dirt build-up, providing a deep clean for wood or hard-surface floors. The ready-to-use, oxygenated, waterbased formula releases thousands of micro-bubbles that loosen heavy dirt build-up, removes stuck-on messes, and lifts away stains via a bubbling action to provide a deep clean for floors.
Formulated specifically for cleaning pet messes, The Bona Pet System Hard Surface Floor Deep Cleaner and Bona Pet System Wood Floor Deep Cleaner offer a deep clean by penetrating through tough stuck-on stains, tracked in dirt, and accident messes with the cleaning power of Hydrogen Peroxide. The Odour Guard Technology™ eliminates and neutralizes urine and other organic odours upon contact.
For more information about Bona Pet System and OxyPower cleaners are visit www.bona.com. These GREENGUARD certified products are available in EMEA and APAC regions.
“These four cleaning products were developed to meet the high standards of consumers as well as certifying organizations like the EPA Safer Choice program,” continued Shore. “With 11 Safer Choice certified products in North America it made sense to seek this certification for our products in Europe. It all aligns to our long-standing mission to minimize our environmental impact by innovating safer systems and products to the highest sustainability standards.”
About the EPA Safer Choice Program
Safer Choice incentivizes safer, greener chemistry by allowing companies to differentiate their products in the marketplace with the Safer Choice label. With thousands of certified products, the Safer Choice label is a reliable way to find products made with safer ingredients without sacrificing performance. For more information about the Safer Choice program, visit: www.epa.gov/saferchoice.
About Bona®
Bona® is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. Bona’s turnover is 4.1bn SEK (EUR 366million) 2023. The head office is in Malmö, Sweden, and the company is represented globally by its 17 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318768884/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
